HASBROUCK HEIGHTS, N.J., April 18 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) announced today completion of a new 42 month
follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study
evaluated symptomatic progress of U.S. patients involved in the Company's two
Phase 1-2 studies initiated in 2003. Individuals in the study were assessed
for symptomatic improvement, treatment outcomes, and durability of efficacy.
Patients in the study were assessed 3 1/2 years after NX-1207 treatment. The
Company expects to conclude analysis of the data in the next 1-2 weeks and
will be reporting the results once they are completed.
NX-1207 has successfully completed three U.S. trials to date. The
company's most recently reported trial, a Phase 2 double-blind, placebo
controlled, randomized study, showed positive efficacy and safety results for
NX-1207 after 3 months in patients with BPH. Overall, patients treated with
NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom
Score values, the standard scale used to evaluate BPH drugs and treatments.
This improvement compares favorably to the 3.5 to 5 points reported in
published studies of currently approved drugs for BPH and reached statistical
significance when compared to placebo. Subjects treated with NX-1207 also
showed an overall significant reduction in mean prostate volume. The results
of the trial demonstrated the excellent safety and side effect profile of
NX-1207. Subjects treated with NX-1207 had no serious side effects. In
particular, patients given NX-1207 had no (0%) significant sexual side
BPH afflicts approximately half of men over age 50 and close to 90% of
men by age 80. The disorder causes difficulties with urination associated with
aging, such as urination at night, urge to void frequently, hesitancy, weak
stream, and other problems.
More information about Nymox is available at www.nymox.com, email:
email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products involve
substantial risks and uncertainties and actual results may differ materially
from expectations. Promising early results do not ensure that later stage or
larger scale clinical trials will be successful or will proceed as expected.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,